advanced search
Dr Jnanadeva Bhat
Vice-President and Head of R&D (Pharma & Nutra)
ACG

Is this your profile?

About

Jnanadeva Bhat, PhD, is Vice-President and Head of R&D (Pharma & Nutra) at ACG Group. He has been associated with the pharmaceutical industry for nearly three decades. As a product formulator, he has worked on various dosage forms, including tablets, soft gelatin and hard capsules, injectables and lyophilised formulations. At ACG, Dr Bhat heads the formulation R&D lab where he primarily leads new product development projects and customer interface.

Contributions

EXPERT VIEW
STRATEGIES TO MITIGATE GELATIN CROSS-LINKING IN ORAL SOLID DRUG DELIVERY
Jnanadeva Bhat and Manali Dalvi discuss the factors contributing to gelatin cross-linking in oral solid dose delivery – and strategies to tackle the resulting challenges.

More contributions

EXPERT VIEW
HARD CAPSULES: A HOLISTIC APPROACH FOR ORAL DRUG DELIVERY AND FORMULATION
Jnanadeva Bhat and Manali Dalvi discuss how advances in capsule technology as an oral drug delivery method have opened up new avenues for the development of more effective and patient-friendly drugs.
EXPERT VIEW
CAPSULES: CLASSIC DRUG DELIVERY FORM HOLDS POTENTIAL FOR SUSTAINABLE DELIVERY
Jnanadeva Bhat and Anita Solanki discuss the role that hard capsules are able to play in delivering a more sustainable pharmaceutical industry, both as an oral solid dosage form and in dry powder inhalers.
EXPERT VIEW
CAPSULES FOR DRY POWDER INHALATION – A COMPLETE PRODUCT
Anita Solanki, Jnanadeva Bhat and Justin Kalafat discuss capsules for dry powder formulation and consider their potential as a dosage form for patients with respiratory conditions and systemic illnesses.
PULMONARY
THE SCIENCE BEHIND CAPSULE-BASED DRY POWDER INHALATION TECHNOLOGY
Here, Fernando Díez, Justin Kalafat, and Jnanadeva Bhat explain the mechanics behind cDPIs, from the scientific perspective, before looking to the future of cDPIs in the market.
Top